SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...
Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program ...
The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.
Volastra Therapeutics, a clinical-stage biotechnology company pioneering first-in-class therapies targeting chromosomal ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following ...
Over the past decade, a shift has been occurring in biopharma R&D. Despite great advancements in drug technologies and our understanding of diseases, it is getting harder to develop new drugs and ...
FDA Clears IND Allowing Phase 2a Trial of NAV-240 in Hidradenitis Suppurativa to Begin Dosing in Q1 2026HREC Approval ...
Instil Bio said its subsidiary has discontinued clinical development of AXN-2510 and terminated its collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) for AXN-2510 and AXN-27M.
After more than two years of pandemic-driven growth, Labcorp is shipping off its clinical development arm as a standalone, public company. The spinoff—for now, dubbed the “clinical development ...
A systematic approach that views the clinical research department as an integral part of the development team can enhance the likelihood of success in the creation of new products. Nancy J. Stark Many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback